{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.08","value":"2.1"},{"groupId":"OG001","spread":"2.07","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.35","value":"1.6"},{"groupId":"OG001","spread":"1.37","value":"2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.34","value":"1.6"},{"groupId":"OG001","spread":"1.79","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.39","value":"1.9"},{"groupId":"OG001","spread":"1.73","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.94","value":"1.8"},{"groupId":"OG001","spread":"1.20","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"All cycles"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"The time to ANC recovery post nadir for each patient, for each of their chemotherapy cycles will be recorded. Recovery for this protocol is defined as achieving an ANC ≥ 2.0 × 10\\^9/L after the expected ANC nadir (expected nadir is typically 4-6 days post chemotherapy administration).","dispersionType":"Standard Deviation","groups":[{"description":"F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.","id":"OG000","title":"F-627"},{"description":"Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"3 Subjects terminated early (1 in F-627 arm, 2 in the placebo arm). In addition, 1 subject in placebo arm reached her Nadir(1.81) at Day 7 but the rest of ANC values are missing. Because the recovery information is not available, this subject was removed from the Time to ANC recovery analysis.","reportingStatus":"POSTED","timeFrame":"4 chemotherapy cycles, about 12 weeks","title":"The Time in Days to ANC Recovery Post Nadir for Each Chemotherapy Cycle and Over All Cycles; Recovery Defined as an ANC ≥ 2.0 × 10^9/L After the Expected ANC Nadir.","type":"SECONDARY","unitOfMeasure":"days"}